Richter, Evestra sign $ 5 mln loan agreement
Hungarian drugmaker Gedeon Richter and Texas-based biopharmaceutical company Evestra announced today that they have signed a collaboration agreement in which Richter is providing a $5 mln convertible loan to Evestra, so that firm can accelerate the development of its innovative women’s health product pipeline into clinical stages.
Under the terms of the agreement, after three years Richter has the option to determine whether the loan will be reimbursed, including earned interest, or converted into an equity stake in Evestra, the statement added.
Evestra is engaged in the development of innovative women’s healthcare products, the press release said. Evestra’s products are based on two platform technologies, medicinal chemistry and vaginal drug delivery technology, and they address unmet medical needs in women's healthcare, the release added.
Richter's consolidated sales were approximately €1.1 bln ($1.5 bln), while its market capitalization amounted to €2.1 bln ($2.5 bln) in 2014, according to the statement. Richter’s product portfolio includes a therapeutic range, including gynecology, central nervous system, and cardiovascular fields. According to the statement Richter has the largest R&D unit in CEE, which focuses on CNS disorders.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.